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Abstract: For decades, doxorubicin alone or in combination with 
ifosfamide has been used in advanced soft tissue sarcoma (STS). In 2014 a 
comparison of doxorubicin alone vs the combination with ifosfamide (in 
the randomized phase III EORTC 62012) showed no difference in overall 
survival (OS) but a difference in response and progression free survival 
(PFS) were observed in favour of the combination but at the expense of 
increased toxicity. Newer, less toxic, fosfamides namely evofosfamide and 
palifosfamide have recently been tested in randomized phase III clinical 
trials in STS in an attempt to minimize toxicity. The TH CR-406/SARC021 
(June 2017) and the PICASSO III (Sept 2016) studies compared doxorubicin, 
as the standard arm, to doxorubicin in combination with evofosfamide and 
palifosfamide respectively. In both studies the combination arm produced 
increased response rates but at the expense of higher toxicity. However, 
there was no difference in OS or PFS in favour of the combination. 
Importantly the median OS of patients receiving standard of care, 
doxorubicin, in both studies appeared improved from 12.8 months (95·5% CI 
10·5-14·III) in the EORTC 62012 to 16.9 months (95% CI 14.8 to 22.9) in 
PICASSO III and 19·0 months (95% CI 16·2-22·4) in TH CR-406/SARC021.  
The results of these three randomized phase III studies highlight several 
critical issues related to the design and conduct of such trials in STS. 
We discuss these issues aiming to contribute to the ongoing debate about 
the optimal approach to perform clinical research in STS.  
 
 
 
 
 
  
 
To the Editor-in-Chief of the European Journal of Cancer  
June 14th 2017 
 
Dear Professor Eggermont, 
We respectfully submit our manuscript entitled “The fate of new fosfamides in phase III studies in 
advanced soft tissue sarcoma” for editorial consideration and publication in the European Journal of 
Cancer.  
Recently the TH CR-406/SARC021 study results were published on line in Lancet Oncology comparing 
evofosfamide plus doxorubicin to doxorubicin single agent (Tap et al, Lancet Oncology, June 23 2017 
epub ahead of print) in advanced soft tissue sarcoma. This study was highlighted in the ASCO Post 
last week. The study did not meet its primary endpoint and it is the third phase III study in advanced/ 
metastatic soft tissue sarcoma over the last 4 years a “fosfamide” compound combination arm 
versus monotherapy doxorubicin showing lack of survival benefit of the combination arm. 
Conduct of clinical research in soft tissue sarcoma remains challenging, owing not only to the rarity 
and the heterogeneity of the disease but also to limitations in the clinical trial design. Important 
information derived from randomized controlled trials such as the TH CR-406/SARC021and the 
PICASSO III (palifosfamide plus doxorubicin versus doxorubicin plus placebo, Ryan et al, Journal of 
Clinical Oncology, 2016) should be used to guide efforts in the design of future clinical studies in soft 
tissue sarcoma. We discuss critical points raised by these 2 studies and in relation to the benchmark 
EORTC 62012 study (Ifosfamide plus doxorubicin versus doxorubin, Judson et al, Lancet Oncology 
2014).  
With this Current Perspective we aim to contribute to the ongoing debate about trial design in rare 
and heterogeneous cancers, such as sarcomas, to prevent further costly negative phase III studies 
with new compounds in this disease. 
 
With kind regards  
Professor Winette T.A. van der Graaf 
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Highlights  
- Newer, less toxic, fosfamides namely evofosfamide and palifosfamide have recently 
been tested in randomized phase III clinical trials in soft tissue sarcoma in an attempt to 
minimize toxicity. 
- In the TH CR-406/SARC021 (June 2017) and the PICASSO III (Sept 2016) the 
combination arm (doxorubicin in combination with evofosfamide and palifosfamide 
respectively) produced increased response rates compared to doxorubicin alone but at the 
expense of higher toxicity. 
- The median OS of patients with advanced disease receiving standard of care 
treatment (doxorubicin) in first line phase III studies has improved over the last decade from 
12.8 months (95·5% CI 10·5–14·3) (EORTC 62012) to 16.9 months (95% CI 14.8 to 22.9) 
(PICASSO III) and 19·0 months (95% CI 16·2–22·4) (TH CR-406/SARC021). 
- Balancing different subtypes between two treatment arms is extremely challenging in 
phase III studies in a biologically and clinically heterogeneous disease such as soft tissue 
sarcoma therefore to the extent that this is feasible, efforts should be made to focus on 
specific tumour subtypes. To illustrate, the subgroup of synovial sarcomas in the TH CR-
406/SARC021, had a significant overall survival benefit from the combination therapy, but a 
prospective trial needs to proof that.   
- More emphasis should be placed on the appropriate design and conduct of clinical 
trials in soft tissue sarcoma. 
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Abstract: 
For decades, doxorubicin alone or in combination with ifosfamide has been used in 
advanced soft tissue sarcoma (STS). In 2014 a comparison of doxorubicin alone vs the 
combination with ifosfamide (in the randomized phase III EORTC 62012) showed no 
difference in overall survival (OS) but a difference in response and progression free survival 
(PFS) were observed in favour of the combination but at the expense of increased toxicity. 
Newer, less toxic, fosfamides namely evofosfamide and palifosfamide have recently been 
tested in randomized phase III clinical trials in STS in an attempt to minimize toxicity. The TH 
CR-406/SARC021 (June 2017) and the PICASSO III (Sept 2016) studies compared 
doxorubicin, as the standard arm, to doxorubicin in combination with evofosfamide and 
palifosfamide respectively. In both studies the combination arm produced increased 
response rates but at the expense of higher toxicity. However, there was no difference in OS 
or PFS in favour of the combination. Importantly the median OS of patients receiving 
standard of care, doxorubicin, in both studies appeared improved from 12.8 months (95·5% 
CI 10·5–14·III) in the EORTC 62012 to 16.9 months (95% CI 14.8 to 22.9) in PICASSO III 
and 19·0 months (95% CI 16·2–22·4) in TH CR-406/SARC021.  
The results of these three randomized phase III studies highlight several critical issues 
related to the design and conduct of such trials in STS. We discuss these issues aiming to 
contribute to the ongoing debate about the optimal approach to perform clinical research in 
STS.  
 
 
  
Sarcomas are a rare group of heterogeneous mesenchymal tumours comprising over 70 
histological subtypes of varying underlying biological and clinical behaviour (1). Management 
is challenging because of the rarity and the diversity of the disease. Despite significant 
advances in the molecular characterisation and classification of sarcomas, effective targeted 
therapy has only truly influenced the outcomes of patients with gastrointestinal stromal 
tumours with activating mutations in KIT or PDGFRA after the introduction of multitargeted 
tyrosine kinase inhibitors (2). In contrast, for most soft tissue sarcomas (STS), conventional 
chemotherapy remains the standard systemic option in the  advanced/metastatic setting with 
two drugs monopolising first line treatment over the last few decades: doxorubicin (3, 4) and 
ifosfamide (5). For many years, empirically, doxorubicin was used as monotherapy or in 
combination with ifosfamide. A head to head comparison of the two regimens (EORTC 
62012: doxorubicin alone or in combination with ifosfamide) in a randomized controlled 
phase III trial (RCT) reported in 2014 showed no difference in overall survival (OS) although 
a difference in progression free survival (PFS) in favour of the combination was noted at the 
expense of increased toxicity (6).   
Ifosfamide is an alkylating agent undergoing transformation in the liver to become active. 
The toxicity profile of ifosfamide, primarily the risk of bone marrow suppression, 
haemorrhagic cystitis and encephalopathy, has provided the rationale for the development of 
newer analogues with less toxic metabolites. One such agent, palifosfamide, is a tris salt of 
isophosphoramide mustard, the active metabolite of ifosfamide. Another analogue is 
evofosfamide, a hypoxia-activated prodrug of bromo-isophosphoramide mustard, which 
under hypoxic conditions, can function as a DNA cross-linking agent (7). Tap et al. report in 
the Lancet Oncology (June 23 2017 epub ahead of print) the results of TH CR-
406/SARC021, a phase III, multicentre, randomized, open-label trial assigning patients with 
advanced or metastatic STS to receive either doxorubicin alone or in combination with 
evofosfamide as first line treatment, with continuation of evofosfamide in non-progressive 
patients (8). Evofosfamide had previously demonstrated activity against advanced STS in 
combination with doxorubicin in a single arm phase II trial of 91 patients (9) reaching a 
median OS of 21·5 months (95% CI 16·0–26·2) and a median PFS of 6·5 months (95% CI 
5·8–7·7). 
One of the main hurdles in clinical research in sarcoma is the difficulty to design and conduct 
large prospective RCT within reasonable timelines. Given these limitations the authors of the 
TH CR-406/SARC021 should be congratulated for performing and completing this phase III 
study in a timely manner (enrolment of 640 patients between September 2011 and January 
2014). Patients were eligible if they were 15 years and over, had advanced or metastatic 
STS with no standard curative therapy available, measurable disease and performance 
status of 0–1. The primary objective was OS in the intention-to-treat population. Secondary 
end points included PFS and overall response rate. Patients were randomly assigned to a 
maximum of 6 cycles of doxorubicin 75mg/m2 intravenously on day 1 of every 21-day cycle, 
or doxorubicin plus evofosfamide 300 mg/m2 intravenously on days 1 and 8 of every 21-day 
cycle, plus continuation of single agent evosfosfamide in non-progressive patients. The OS 
endpoint was not reached (HR 1·06, 95% CI 0·88–1·29; p=0·527) but the median OS was 
18·4 months (95% CI 15·6–22·1) with doxorubicin plus evofosfamide versus 19·0 months 
(95% CI 16·2–22·4) with doxorubicin alone. Remarkable benefit was seen in the subgroup of 
31 synovial sarcoma patients with a HR 0·III2 [95% CI 0·14–0·73III; p=0·0043] in favour of 
the combination treatment. 
Median PFS was similar in the two groups (6·3 months (95% CI 6·0–7·8) in the combination 
group vs 6·0 months (95% CI 4·6–6·2) in the doxorubicin alone group). In contrast, the 
proportion of patients who achieved complete or partial response was significantly higher in 
the combination group than in the doxorubicin alone group (28% vs 18% of patients; 
p=0·0026). A complete and partial response was documented in 2% and 27% of patients 
treated with the combination, respectively, and in 1% and 17%, respectively, with 
doxorubicin alone. The proportion of patients achieving disease control (complete response, 
partial response, or stable disease) was 73% in the combination group and 66% in the 
doxorubicin alone group (odds ratio 1·49 [95% CI 0·54–1·36], p=0·0473).  
These results raise two critically important points. The first one is that TH CR-406/SARC021 
is yet another randomized controlled phase III study in the recent history of clinical trials in 
advanced STS to show no difference in PFS or OS between the experimental arm and the 
control arm; potentially rendering the new agent (in this occasion evofosfamide) ‘non 
interesting’ in sarcoma in the eyes of the pharmaceutical industry. The second point is that 
TH CR-406/SARC021 and other studies reported recently including PICASSO III (a phase 
III, multicentre, randomized, double-blind, placebo-controlled trial assigning patients with 
STS to receive either doxorubicin plus palifosfamide or doxorubicin plus placebo, as first line 
treatment)(10) have shown an impressive increase of the median OS in the control arm 
compared to what studies in the past had shown (EORTC 62012). It appears that the 
median OS of patients with advanced disease receiving standard of care treatment 
(doxorubicin) in first line phase III studies has improved over the last decade from 12.8 
months (95·5% CI 10·5–14·3) (EORTC 62012) to 16.9 months (95% CI 14.8 to 22.9) 
(PICASSO III) and 19·0 months (95% CI 16·2–22·4) (TH CR-406/SARC021) (table 1). 
Given these two facts, the burning question about TH CR-406/SARC021 is whether the 
benefit of the novel agent is indeed absent or whether the control arm is too good to allow 
the detection of any potential benefit. There are now two similar examples of promising 
ifosfamide alike agents in sarcoma, palifosfamide and evofosfamide, where phase III trials 
failed to confirm therapeutic benefits seen in randomized phase II studies (9, 11). Whilst this 
phenomenon can be attributed to the limitations of study design in randomized trials in 
heterogeneous diseases like STS, other possible explanations include the incorporation of 
newer treatments in sarcoma therapeutics particularly in second line treatment and beyond, 
local procedures in metastatic setting, as well as important advances in palliative and 
supportive care. One should also consider - as a possible contributing factor - the increased 
emphasis now placed on accurate histological diagnosis of soft sarcoma subtypes using 
central pathology review to better specify sarcoma subtypes and to avoid inclusion of non 
sarcoma malignancies in clinical trials (with worse prognosis and worse response to 
doxorubicin) which may have partly masked the true median OS of the standard 
chemotherapy in the past. This is also illustrated in a second analysis of the EORTC 62012 
study based on central pathology review showing an OS benefit for the undifferentiated 
pleiomorphic subgroup (12). 
Setting PFS or OS as the primary end point in RCT in STS has been under debate for years. 
Noticeably, in the EORTC 62012 trial the primary end point was OS benefit but this was 
subsequently criticized as a complex and easily confounded measure of therapeutic efficacy 
over PFS and response rate in a diverse group of rare diseases such as STS, where 
perhaps the bar of treatment success was  set too high (13). Interestingly, when PICASSO 
III was originally designed the primary end point was OS but in order to obtain accelerated 
approval by the US Food and Drug Administration– and following completion of recruitment 
of all patients - the primary end point was changed to PFS without altering the sample size 
or the statistical considerations made at the start.  In the TH CR-406/SARC021 PFS was not 
set as the primary end point because of concerns that it could have been confounded by 
inherent weaknesses introduced by the design of the study, such as the absence of placebo 
or study blind. Data provided by real life observational studies such as the recently published 
METASARC (14) highlight the limitations associated with the design and outcomes of clinical 
trials. Time to next treatment (TNT) is suggested as a surrogate endpoint for OS given their 
strong correlation.  
Despite the lack of OS benefit, the proportion of patients who achieved complete or partial 
response was significantly higher in the doxorubicin plus evofosfamide group than in the 
doxorubicin alone group. Similarly in the PICASSO III there were more objective responses 
among patients treated with doxorubicin plus palifosfamide than with doxorubicin plus 
placebo; and interestingly response rates in both arms were similar to those reported in 
EORTC 62012. The results of all three studies show that response rate results have limited 
clinical significance in the absence of survival benefit in STS and, as was shown in the 
EORTC 62012, absence of progression could be used as a better surrogate for final 
outcome (15). 
Apart from differences in histological subtypes, the biological behaviour and progress of 
metastases in STS can also differ substantially. Without the requirement of documented 
progression within a well-defined time period before the start of a study the risk of 
introducing unwanted bias is realistic. The attraction to put patients on a competitive clinical 
study with a new drug may introduce a selection of relatively fit patients with lower volume 
metastatic disease. Prolongation of median PFS to over 6 months in patients treated with 
single agent doxorubicin could be an indirect reflection of this statement.  As shown in table 
2 this information is not provided in the TH CR-406/SARC021 or the PICASSO III although 
one can appreciate how imbalance in the disease progression status between the groups 
could have easily affected the survival outcomes in favour of either of the groups. The 
importance of this observation is lying in the potentially critical role of ensuring homogeneity 
of clinical/phenotypical data for patients entering clinical trials; in the absence of 
representative biomarkers and given the biological heterogeneity of the disease, enrolling 
only patients with the same disease status (i.e. well-defined progressive disease) is 
important in testing novel agents in STS. The EORTC 62012 study has been the only one 
requiring documented progression within the last 6 weeks before study entry and as such 
has probably had patients with more aggressive phenotype on study, leading to the shortest 
OS of the trials as described. 
In recent years there has been criticism about the ‘one size fits all’ approach in clinical trials 
design in STS where a specific drug or regimen is given to various histological subtypes 
lumped together; it has been clear for some time now that certain STS histologies respond 
better than others to particular agents (16) and lumping different subtypes together may lead 
to inaccurate and misleading conclusions. Balancing different subtypes between two 
treatment arms is extremely challenging in a disease that contains over 70 histological 
subtypes. In the TH CR-406/SARC021 by and large this balance was achieved between the 
2 arms (leiomyosarcoma 35% vs 37%, liposarcoma 15% vs 20%) whereas in the PICASSO 
III trial some subgroups were less or not balanced (liposarcoma 11.9% vs 18.1% and 
pleomorphic/undifferentiated/sarcoma, NOS 37.6% vs 28.5%) (table 3). Therefore, to the 
extent that this is feasible, efforts should be made to focus on specific tumour subtypes.  
In terms of safety, in both the PICASSO III and the TH CR-406/SARC021, patients in the 
combination arms experienced more grade 3 and 4 adverse events compared to single 
agent doxorubicin although the toxicity profile of the newer “fosfamides” (palifosfamide and 
evofosfamide) appeared better than that of ifosfamide.  
 
Conclusion:  
Design and conduct of clinical research in STS is hampered by the rarity and the 
heterogeneity of the disease. With advances to date, the therapeutic landscape has started 
to change. Important information derived from RCT trials such as the TH CR-406/SARC021 
and the PICASSO III should be used to guide future efforts in clinical and translational 
research. Collaborative efforts are required to ensure that trial design should lead to as 
homogeneous groups to compare as possible within the framework of meaningful statistics. 
Median OS should be reconsidered in control arms of randomised studies taking the 
biological behaviour of soft tissues sarcomas into account. 
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SARC 021: Doxorubicin versus doxorubicin plus evofosfamide 
PICASSO: Doxorubicin plus placebo versus doxorubicin plus palifosfamide 
EORTC 62012: Doxorubicin versus doxorubicin plus ifosfamide 
 
Table 1. Accrual and Endpoints of the trials 
 
 
 
 
 
Trial Progression before 
study entry 
Percentage female 
patients 
Doxorubicin vs 
combination 
Median age (year) 
Doxorubicin versus 
combination 
SARC 021 Not required 53 vs 55 58 vs 50 
PICASSO Not mentioned 47 vs 46 56 vs 58 
EORTC 62012 Yes within 6 weeks 
before start 
 (RECIST 1.0) 
55 vs 50 48 vs 47 
 
Table 2. Phenotypical characteristics 
 
 
 
 
 
Trial Pathology 
review 
Leiomyo- 
sarcoma 
(%) 
D vs C 
Liposarcoma 
(%) 
 
D vs C 
Synovial 
sarcoma 
(%) 
D vs C 
UPS (%) 
 
 
D vs C 
Other 
(%) 
 
D vs C 
SARC 021 Central 32 vs 36 16 vs19 3 vs 5 25 vs 21 8 vs 3 
PICASSO Central 31 vs 30 18 vs 12 5 vs 5 29 vs 38 10 vs 7 
EORTC 
62012 
Local 24 vs 26 11vs 14 17 vs 11 Not 
mentioned 
48 vs 49 
 
Table 3. Histology in the different trials. D= doxorubicin, C= combination of doxorubicin and 
evofosfamide (SARC 021), palifosfamide (PICASSO III) and ifosfamide (EORTC 62012), 
UPS= Undifferentiated Pleiomorphic Sarcoma 
 
Trial Primary 
endpoint 
Accrual 
period 
Number 
of 
patients 
RR (%) 
doxorubicin 
versus 
combination 
PFS 
(months) 
doxorubicin 
versus 
combination 
OS (months) 
doxorubicin 
(plus 
placebo) 
versus 
combination 
SARC 021 OS 2011-14 640 18 vs 28 6.0 vs 6.3 19.0 vs 18.4 
      95% CI 4·6–6·2 
   vs 6·0–7·8 
95% CI 16·2–22·4 
        vs 15·6-22·1 
PICASSO PFS 2010-12 447 20 vs 28 5.2 vs 6.0 16.9 vs 15.9 
      95% CI 4.2 - 6.0 
         vs 5.4 - 6.5 
95% CI 14.8 - 22.9 
     vs 13.7 - 19.4 
EORTC 
62012 
OS 2003-10 455 14 vs 26 4.6 vs 7.4 12.8 vs 14.3 
       95% CI 2·9–5·6 
      vs 6·6–8·3 
 95% CI 10·5–14·3  
         vs 12·5–16·5 
Table
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